WEZEL PHARMA
ActiveSummary
WEZEL PHARMA has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €309,290 and a net result of €52,338. Equity is growing by about 18% per year across the filed financial years. Its solvency ranks better than 73% of 12,464 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
02-07
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
01-07
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format
2024
01-07
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format
2023
04-07
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format
2022
31-12
Financial
Highest result from 2021 to 2025net €100,836 ▲9.9%
Operating result €140,376, net result €100,836, both a record.
31-12
Financial
Equity above €200,000equity €205,093 ▲96.7%
A profit in every financial year since 2021 builds equity to €205,093.
03-07
NBB filing
Annual accounts filed
financial year 2021 · abbreviated format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 1 deed read
About the unread acts
We know of 1 Belgian Official Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.